Clinical Trial Update: Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant pembrolizumab with IO102-103 for head and neck squamous cell carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• IO102-103
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING